Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

The Tumor Microenvironment02:17

The Tumor Microenvironment

6.3K
Every normal cell or tissue is embedded in a complex local environment called stroma, consisting of different cell types, a basal membrane, and blood vessels. As normal cells mutate and develop into cancer cells, their local environment also changes to allow cancer progression. The tumor microenvironment (TME) consists of a complex cellular matrix of stromal cells and the developing tumor. The cross-talk between cancer cells and surrounding stromal cells is critical to disrupt normal tissue...
6.3K
Targeted Cancer Therapies02:57

Targeted Cancer Therapies

7.0K
The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against...
7.0K
Cytotoxic T Cells-mediated Immune Response01:27

Cytotoxic T Cells-mediated Immune Response

7.0K
Cytotoxic T cells are a vital component of the immune system. They have the remarkable ability to identify and target antigens on infected or abnormal cells. These antigens often originate from intracellular pathogens such as viruses or abnormal proteins cancer cells produce.
Immunological surveillance is the ability of immune cells to monitor and eliminate infected cells with intracellular pathogens, neoplastically transformed cells, and cells with non-self antigens. Cytotoxic T cells and NK...
7.0K
Lymphoid Cells and Tissues01:18

Lymphoid Cells and Tissues

3.4K
Lymphoid cells and tissues are integral to the immune system, which is crucial in maintaining our body's defense against harmful pathogens. They form the building blocks of lymphoid organs, which include the spleen, thymus, and lymph nodes.
Lymphoid cells consist of various types of immune system cells. These include B and T lymphocytes, which are responsible for producing antibodies and killing infected cells, respectively. Dendritic cells act as messengers between the innate and adaptive...
3.4K

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Beyond MURANO: sequencing therapy in relapsed chronic lymphocytic leukaemia.

Lancet (London, England)·2026
Same author

CD4+ cell count trends after common cancers in people with HIV: a multicohort collaboration.

AIDS (London, England)·2026
Same author

EHA Guidelines on management of chronic lymphocytic leukemia and Richter transformation.

HemaSphere·2026
Same author

​EuroNet-PHL-LP1: Complete resection or low-dose chemo for pediatric low-risk nodular lymphocyte-predominant Hodgkin lymphoma.

Blood advances·2026
Same author

Systemic and Local Adiposity in the Bone Marrow Microenvironment Associated With Improved Prognosis in Hodgkin Lymphoma: Imaging and Molecular Analysis.

International journal of cancer·2026
Same author

Monocyte-mediated metabolic rewiring via CD31-CD38 interactions promotes growth and drug-resistance in multiple myeloma.

HemaSphere·2026

Related Experiment Video

Updated: Apr 25, 2026

Modeling Chemotherapy Resistant Leukemia In Vitro
08:41

Modeling Chemotherapy Resistant Leukemia In Vitro

Published on: February 9, 2016

8.6K

How does lenalidomide target the chronic lymphocytic leukemia microenvironment?

Arnon P Kater1, Sanne H Tonino1, Alexander Egle2

  • 1Department of Hematology and Lymphoma and Myeloma Centre Amsterdam (LYMMCARE), Academic Medical Center, Amsterdam, The Netherlands;

Blood
|August 28, 2014
PubMed
Summary

Lenalidomide immunotherapy repairs T-cell function, showing promise in chronic lymphocytic leukemia (CLL) and lymphoma trials. This review details its mechanism, clinical updates, and future potential in targeted cancer therapy.

More Related Videos

Chemical Inactivation of the E3 Ubiquitin Ligase Cereblon by Pomalidomide-based Homo-PROTACs
10:44

Chemical Inactivation of the E3 Ubiquitin Ligase Cereblon by Pomalidomide-based Homo-PROTACs

Published on: May 15, 2019

12.9K
Immunoglobulin Gene Sequence Analysis In Chronic Lymphocytic Leukemia: From Patient Material To Sequence Interpretation
09:02

Immunoglobulin Gene Sequence Analysis In Chronic Lymphocytic Leukemia: From Patient Material To Sequence Interpretation

Published on: November 26, 2018

23.7K

Related Experiment Videos

Last Updated: Apr 25, 2026

Modeling Chemotherapy Resistant Leukemia In Vitro
08:41

Modeling Chemotherapy Resistant Leukemia In Vitro

Published on: February 9, 2016

8.6K
Chemical Inactivation of the E3 Ubiquitin Ligase Cereblon by Pomalidomide-based Homo-PROTACs
10:44

Chemical Inactivation of the E3 Ubiquitin Ligase Cereblon by Pomalidomide-based Homo-PROTACs

Published on: May 15, 2019

12.9K
Immunoglobulin Gene Sequence Analysis In Chronic Lymphocytic Leukemia: From Patient Material To Sequence Interpretation
09:02

Immunoglobulin Gene Sequence Analysis In Chronic Lymphocytic Leukemia: From Patient Material To Sequence Interpretation

Published on: November 26, 2018

23.7K

Area of Science:

  • Immunology
  • Oncology
  • Pharmacology

Background:

  • Immunotherapy is a key strategy for activating antitumor T-cell responses.
  • Lenalidomide is an oral immunomodulatory drug with demonstrated efficacy in hematologic malignancies.
  • Chronic lymphocytic leukemia (CLL) and lymphoma are key areas of investigation for lenalidomide.

Purpose of the Study:

  • To review advances in understanding lenalidomide's mechanism of action within the tumor microenvironment.
  • To provide a clinical update on lenalidomide's efficacy and use in chronic lymphocytic leukemia (CLL).
  • To discuss challenges and future directions for lenalidomide in the context of targeted drug therapies.

Main Methods:

  • Review of preclinical and clinical studies on lenalidomide.
  • Analysis of lenalidomide's immunomodulatory effects on T-cells and the tumor microenvironment.
  • Synthesis of clinical trial data for lenalidomide in CLL and lymphoma.

Main Results:

  • Lenalidomide enhances endogenous antitumor T-cell immunity.
  • The drug demonstrates clinical efficacy in ongoing trials for CLL and lymphoma.
  • Understanding of lenalidomide's mechanism in the tumor microenvironment is advancing.

Conclusions:

  • Lenalidomide is a promising immunomodulatory agent for treating CLL and lymphoma.
  • Further research is needed to optimize its use and overcome associated challenges.
  • Lenalidomide holds potential within the evolving landscape of targeted cancer drug treatments.